FDA approves first-ever two-drug HIV regimen, GSK’s Juluca

pharmafile | November 22, 2017 | News story | Research and Development, Sales and Marketing AIDS, FDA, GSK, Gilead, GlaxoSmithKilne, HIV, Juluca, ViiV Healthcare, pharma 

GlaxoSmithKline has announced that the FDA has awarded US marketing authorisation to the first two-drug regimen in the treatment of HIV.

Juluca, as the therapy is known, is a combination of dolutegravir – an integrase inhibitor from GSK’s majority-owned ViiV Healthcare – and rilpivirine, a non-nucleoside reverse transcriptase inhibitor developed by Johnson & Johnson. It will be available to patients who have been on a stable treatment regimen for at least six months.

The FDA’s conclusion was based data from two late-stage trials in a total of 1024 people, finding that Juluca was non-inferior to three- or four-drug antiretroviral regimens after 48 weeks.

The decision by the US regulator is particularly meaningful for the pharma giant, arming it for the oncoming scuffle with Gilead in the $27 billion per year HIV market. Gilead itself is awaiting a decision from the FDA, due in February, on its triple-drug combination containing bictegravir, which was found in July to be non-inferior to regimens containing dolutegravir in July.

The therapy has been indicated by GSK CEO Emma Walmsley as one-third of the company’s key strategy to reclaiming revenue lost by its failing lung drug Advair, alongside its chronic lung disease inhaler Trelegy Ellipta and its shingles vaccine Shingrix, approved in the US in September and October respectively.   

“Based on the fundamental principle that no one should have to take more medicines than necessary, ViiV Healthcare has put in place a comprehensive 2-drug regimen research and development programme built around the characteristics of dolutegravir,” explained John C Pottage, Chief Scientific and Medical Officer, ViiV Healthcare. “Juluca, our new 2-drug regimen, once-daily, single pill, now provides people living with HIV who are virologically suppressed, the option to reduce the number of antiretrovirals they take, while maintaining the efficacy of a traditional three-drug regimen.”

Matt Fellows

Related Content


GSK shares data from global shingles survey

GSK has announced data from its new global survey about shingles. The data suggests that …

FDA accepts NDA for Karuna’s schizophrenia treatment

Karuna Therapeutics has announced that the US Food and Drug Administration (FDA) has accepted its …

Vivos Therapeutics gains FDA 510(k) clearance for sleep apnea treatment device

Vivos Therapeutics has announced that it has received 510(k) clearance from the US Food and …

Latest content